Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Development of MicroRNA Therapeutics for Hepatocellular Carcinoma.

Aravalli RN.

Diagnostics (Basel). 2013 Mar 15;3(1):170-91. doi: 10.3390/diagnostics3010170. Review.

2.

Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways.

Thurnherr T, Mah WC, Lei Z, Jin Y, Rozen SG, Lee CG.

Sci Rep. 2016 Jan 28;6:20065. doi: 10.1038/srep20065.

3.

SSRP1 Contributes to the Malignancy of Hepatocellular Carcinoma and Is Negatively Regulated by miR-497.

Ding Q, He K, Luo T, Deng Y, Wang H, Liu H, Zhang J, Chen K, Xiao J, Duan X, Huang R, Xia Z, Zhou W, He J, Yu H, Jiao X, Xiang G.

Mol Ther. 2016 May;24(5):903-14. doi: 10.1038/mt.2016.9. Epub 2016 Jan 12.

4.

The Roles of MicroRNA-122 Overexpression in Inhibiting Proliferation and Invasion and Stimulating Apoptosis of Human Cholangiocarcinoma Cells.

Liu N, Jiang F, He TL, Zhang JK, Zhao J, Wang C, Jiang GX, Cao LP, Kang PC, Zhong XY, Lin TY, Cui YF.

Sci Rep. 2015 Dec 21;5:16566. doi: 10.1038/srep16566.

5.

Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis.

Novák J, Olejníčková V, Tkáčová N, Santulli G.

Adv Exp Med Biol. 2015;887:79-100. doi: 10.1007/978-3-319-22380-3_5. Erratum in: Adv Exp Med Biol. 2015;888:E1-2.

6.

Elevating microRNA-122 in blood improves outcomes after temporary middle cerebral artery occlusion in rats.

Liu da Z, Jickling GC, Ander BP, Hull H, Zhan X, Cox C, Shroff N, Dykstra-Aiello C, Stamova B, Sharp FR.

J Cereb Blood Flow Metab. 2016 Aug;36(8):1374-83. doi: 10.1177/0271678X15610786. Epub 2015 Oct 19.

7.

Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.

Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ, Cai YJ, Yang NB, Zheng MH, Dong JZ, Zhang L, Chen YP.

Oncotarget. 2015 Sep 22;6(28):25093-108. doi: 10.18632/oncotarget.4437.

8.

Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish.

Evason KJ, Francisco MT, Juric V, Balakrishnan S, Lopez Pazmino Mdel P, Gordan JD, Kakar S, Spitsbergen J, Goga A, Stainier DY.

PLoS Genet. 2015 Jul 2;11(7):e1005305. doi: 10.1371/journal.pgen.1005305. eCollection 2015 Jul.

9.

miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, Rashid A, Gagea M, Zabludoff S, Kalluri R, Beretta L.

Cancer Res. 2015 May 1;75(9):1859-67. doi: 10.1158/0008-5472.CAN-14-1254. Epub 2015 Mar 13.

10.

MicroRNAs in Liver Disease: Bench to Bedside.

Shah N, Nelson JE, Kowdley KV.

J Clin Exp Hepatol. 2013 Sep;3(3):231-42. doi: 10.1016/j.jceh.2013.09.001. Epub 2013 Sep 17.

11.

Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach.

Zamanian-Azodi M, Rezaei-Tavirani M, Hasanzadeh H, Rahmati Rad S, Dalilan S.

Gastroenterol Hepatol Bed Bench. 2015 Winter;8(1):6-18. Review.

12.

Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.

Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, Wong CM, Ng IO.

PLoS One. 2014 Dec 26;9(12):e115036. doi: 10.1371/journal.pone.0115036. eCollection 2014.

13.

Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation.

Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A, Kim BH, Kim WB, Yeon JE, Byun KS, Chu IS, Kim SS, Wang XW, Thorgeirsson SS, Luk JM, Kang KJ, Heo J, Park YN, Lee JS.

PLoS Med. 2014 Dec 23;11(12):e1001770. doi: 10.1371/journal.pmed.1001770. eCollection 2014 Dec.

14.

A meta-analysis of microRNA expression in liver cancer.

Yang J, Han S, Huang W, Chen T, Liu Y, Pan S, Li S.

PLoS One. 2014 Dec 9;9(12):e114533. doi: 10.1371/journal.pone.0114533. eCollection 2014.

15.

microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis.

Csak T, Bala S, Lippai D, Satishchandran A, Catalano D, Kodys K, Szabo G.

Liver Int. 2015 Feb;35(2):532-41. doi: 10.1111/liv.12633. Epub 2014 Jul 28.

16.

Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.

Huang S, He R, Rong M, Dang Y, Chen G.

Biomed Res Int. 2014;2014:384121. doi: 10.1155/2014/384121. Epub 2014 May 7.

17.

miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.

Liu AM, Xu Z, Shek FH, Wong KF, Lee NP, Poon RT, Chen J, Luk JM.

PLoS One. 2014 Jan 23;9(1):e86872. doi: 10.1371/journal.pone.0086872. eCollection 2014.

18.

Evaluation of miR-122-regulated suicide gene therapy for hepatocellular carcinoma in an orthotopic mouse model.

Wang G, Dong X, Tian W, Lu Y, Hu J, Liu Y, Yuchi J, Wu X.

Chin J Cancer Res. 2013 Dec;25(6):646-55. doi: 10.3978/j.issn.1000-9604.2013.11.07.

19.

iSubgraph: integrative genomics for subgroup discovery in hepatocellular carcinoma using graph mining and mixture models.

Ozdemir B, Abd-Almageed W, Roessler S, Wang XW.

PLoS One. 2013 Nov 4;8(11):e78624. doi: 10.1371/journal.pone.0078624. eCollection 2013.

20.

Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues.

Rong M, He R, Dang Y, Chen G.

Ups J Med Sci. 2014 Mar;119(1):19-24. doi: 10.3109/03009734.2013.856970. Epub 2013 Oct 31.

Items per page

Supplemental Content

Write to the Help Desk